Pridopidine is a Sigma 1 agonist. It missed both primary endpoints for HD, noting improvement in cognition. Resminostat, the benefits didn't outweigh the side effects. Trial design did not demonstrate how long patients would benefit from the drug. Atropine Sulfate FGK- the effectiveness had not been sufficiently demonstrated. Troriluzole - the main study did not show that Dazluma was more effective than placebo for the treatment of spinocerebellar ataxia. Rechon- no conclusion could be drawn on whether Insulin Human Rechon behaves in the body in the same way as the reference medicine Humulin Regular. Teriparatide Ascend - the study did not allow accurate measurements of the active substance in the body.
Market Data 
Markets 
